- Home
- THCH vs CGEN Comparison
THCH vs CGEN Comparison
Compare THCH & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- CGEN
- Stock Information
- Founded
- THCH 2018
- CGEN 1993
- Country
- THCH China
- CGEN Israel
- Employees
- THCH N/A
- CGEN N/A
- Industry
- THCH Blank Checks
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THCH Finance
- CGEN Health Care
- Exchange
- THCH Nasdaq
- CGEN Nasdaq
- Market Cap
- THCH 141.1M
- CGEN 149.6M
- IPO Year
- THCH N/A
- CGEN 2000
- Fundamental
- Price
- THCH $2.98
- CGEN $1.46
- Analyst Decision
- THCH
- CGEN Strong Buy
- Analyst Count
- THCH 0
- CGEN 1
- Target Price
- THCH N/A
- CGEN $4.00
- AVG Volume (30 Days)
- THCH 16.3K
- CGEN 286.0K
- Earning Date
- THCH 04-17-2025
- CGEN 03-04-2025
- Dividend Yield
- THCH N/A
- CGEN N/A
- EPS Growth
- THCH N/A
- CGEN N/A
- EPS
- THCH N/A
- CGEN N/A
- Revenue
- THCH $207,029,179.00
- CGEN $27,864,000.00
- Revenue This Year
- THCH N/A
- CGEN $22.94
- Revenue Next Year
- THCH N/A
- CGEN $15.88
- P/E Ratio
- THCH N/A
- CGEN N/A
- Revenue Growth
- THCH N/A
- CGEN N/A
- 52 Week Low
- THCH $2.78
- CGEN $1.35
- 52 Week High
- THCH $7.20
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- THCH 44.38
- CGEN 32.02
- Support Level
- THCH $2.78
- CGEN $1.50
- Resistance Level
- THCH $3.05
- CGEN $1.65
- Average True Range (ATR)
- THCH 0.21
- CGEN 0.07
- MACD
- THCH -0.02
- CGEN 0.00
- Stochastic Oscillator
- THCH 27.78
- CGEN 12.50
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.